

ITERIS, INC.  
Form 8-K  
May 16, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **May 16, 2013**

**ITERIS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-08762**  
(Commission File Number)

**95-2588496**  
(IRS Employer Identification No.)

**1700 Carnegie Ave., Suite 100, Santa Ana, California 92705**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(949) 270-9400**

Edgar Filing: ITERIS, INC. - Form 8-K

**Not Applicable**

(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act
  
  - Pre-commencement communications pursuant to Rule 4d-2(b) under the Exchange Act
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
-

**Item 2.02 Results of Operations and Financial Condition.**

The information in this Current Report, including the accompanying exhibit, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

On May 16, 2013, Iteris, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended March 31, 2013. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated May 16, 2013 of the Registrant.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 16, 2013

ITERIS, INC.,  
a Delaware corporation

By:

/s/ James S. Miele  
James S. Miele  
Vice President of Finance and Chief Financial Officer

3

---

es New Roman" style="font-size:10.0pt;">Chiron Corporation

4560 Horton Street

Emeryville, California 94608-2916

510.655.8730 Fax 510.655.9910

**News Release**

**For Immediate Release**

**Contacts:**

Chiron Corporate Communications &

Investor Relations

Media: (510) 923-6500

Investors: (510) 923-2300

**CHIRON ANNOUNCES CHANGE IN STATUS OF SEC INQUIRY**

**EMERYVILLE, Calif., February 11, 2005** Chiron Corporation (NASDAQ: CHIR) announced today that the U.S. Securities and Exchange Commission (SEC) has issued a formal order of investigation with respect to potential violations of federal securities laws. The previously announced informal inquiry began following the suspension by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of Chiron's license to manufacture FLUVIRIN® influenza virus vaccine. Chiron is continuing to cooperate with the SEC's ongoing investigation.

Chiron does not undertake an obligation to update the information in this release.

**About Chiron**

Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information, please visit [www.chiron.com](http://www.chiron.com).

**About Chiron Vaccines**

## Edgar Filing: ITERIS, INC. - Form 8-K

Chiron Vaccines, the world's fifth-largest vaccines business, is headquartered in Oxford, United Kingdom, and has facilities located throughout Europe, the United States and Asia. Chiron Vaccines is the world's second-largest manufacturer of influenza vaccines and has important meningitis, pediatric and travel vaccine franchises. Chiron Vaccines is the leading vaccine manufacturer in the United Kingdom, Germany and Italy. The company's portfolio of products includes vaccines for influenza, meningitis C, rabies, tick-borne encephalitis, yellow fever, haemophilus influenzae B (Hib), polio, mumps, measles and rubella (MMR) and diphtheria, tetanus and pertussis (whooping cough).

NOTE: FLUVIRIN is a trademark of Chiron Corporation.

###

4

---